Teza Capital Management LLC Reduces Position in Elanco Animal Health Incorporated $ELAN

Key Points

• Teza Capital Management LLC significantly decreased its stake in Elanco Animal Health by selling 86,911 shares, reducing its holdings by 87.1% to just 12,907 shares.
• Elanco Animal Health recently reported earnings of $0.26 per share, exceeding estimates and showing a revenue growth of 4.8% compared to the previous year.
• Research firms have varied opinions on Elanco, with Wall Street Zen upgrading it to a "buy" while Zacks Research downgraded it to a "hold."

Teza Capital Management LLC lessened its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 87.1% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 12,907 shares of the company's stock after selling 86,911 shares during the quarter. Teza Capital Management LLC's holdings in Elanco Animal Health were worth $136,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Allworth Financial LP boosted its holdings in shares of Elanco Animal Health by 791.7% during the first quarter. Allworth Financial LP now owns 2,354 shares of the company's stock worth $25,000 after purchasing an additional 2,090 shares during the last quarter. CoreCap Advisors LLC acquired a new stake in shares of Elanco Animal Health during the fourth quarter worth $29,000. Parallel Advisors LLC boosted its holdings in shares of Elanco Animal Health by 92.2% during the first quarter. Parallel Advisors LLC now owns 3,860 shares of the company's stock worth $41,000 after purchasing an additional 1,852 shares during the last quarter. NBC Securities Inc. acquired a new stake in shares of Elanco Animal Health during the first quarter worth $40,000. Finally, Versant Capital Management Inc boosted its holdings in shares of Elanco Animal Health by 65.9% during the first quarter. Versant Capital Management Inc now owns 4,382 shares of the company's stock worth $46,000 after purchasing an additional 1,740 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company's stock.

Elanco Animal Health Stock Down 1.4%

NYSE:ELAN traded down $0.26 during mid-day trading on Friday, hitting $18.52. The company had a trading volume of 5,246,037 shares, compared to its average volume of 10,071,912. The business has a fifty day simple moving average of $16.37 and a 200-day simple moving average of $13.20. The company has a current ratio of 2.60, a quick ratio of 1.40 and a debt-to-equity ratio of 0.61. Elanco Animal Health Incorporated has a 1 year low of $8.02 and a 1 year high of $19.08. The firm has a market capitalization of $9.20 billion, a price-to-earnings ratio of 21.53, a PEG ratio of 3.49 and a beta of 1.62.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.20 by $0.06. Elanco Animal Health had a return on equity of 7.04% and a net margin of 9.68%.The company had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.19 billion. During the same period last year, the company posted $0.30 earnings per share. The firm's revenue was up 4.8% compared to the same quarter last year. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. Equities analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Zacks Research cut Elanco Animal Health from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 20th. Stifel Nicolaus lifted their target price on Elanco Animal Health from $16.00 to $17.00 and gave the company a "buy" rating in a report on Wednesday, July 2nd. Wall Street Zen upgraded Elanco Animal Health from a "hold" rating to a "buy" rating in a report on Saturday, July 5th. Piper Sandler lifted their target price on Elanco Animal Health from $12.00 to $18.00 and gave the company a "neutral" rating in a report on Monday, August 11th. Finally, Leerink Partners upgraded Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 target price on the stock in a report on Thursday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, Elanco Animal Health has a consensus rating of "Moderate Buy" and an average target price of $17.33.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.